Benzinga | Jun 14, 2021 09:51AM EDT

Anavex Life Sciences' Alzheimer's Candidate Mechanism Of Action Explained In Medical Journal

* Anavex Life Sciences Corp (NASDAQ:AVXL) has reported that ANAVEX 2-73 (blarcamesine) and ANAVEX3-71 (AF710B) are featured in a new peer-reviewed publication in the journal of Expert Opinion on Therapeutic Targets.

* Scientific Paper Highlights: Sigma-1 receptor (SIGMAR1)'s expression increases with age. However, in Alzheimer's disease (AD), it decreases and coincides with an age-related decrease in autophagy. The SIGMAR1 may compensate for the loss of receptors and autophagic machinery during healthy aging. ANAVEX-compounds activate SIGMAR1 and induce autophagy, a phenomenon that clears damaged cellular organelles and misfolded proteins. Activation of the SIGMAR1 can induce cytoprotective autophagic pathways. ANAVEX-compounds have also exhibited to block toxic A?, tau, and neuroinflammation.

* Price Action: AVXL shares are up 20.7% at $18.71 during the market session on the last check Monday.